🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against drug-resistant strains of the infection, according to health experts.

An International Public Health Issue

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million new cases annually. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

Based on results published in a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Medical professionals treating patients have expressed positive views. Access to a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.